In this episode of The Meaning of Health, Dr. Craig Cumming, Dr. Monica Tang and Prof. Sallie Pearson explore the recent market withdrawal and subsequent reinstatement of ZOLADEX (goserelin) in Australia. Together, they dissect the gender equity disparities exposed by pharmaceutical market decisions, the systemic underrepresentation of women in clinical trials, and the proactive steps Australia’s health system must take to safeguard equitable access to essential medicines.
Guest Information
Dr. Monica Tang is a Medical Oncologist at Prince of Wales Hospital in Sydney, specialising in breast cancer treatment. She also leads the hospital’s Cancer Survivorship Service, focusing on long-term care and outcomes for cancer patients.
Professor Sallie Pearson is a Health Systems Researcher and Pharmacoepidemiologist at UNSW Sydney. She is dedicated to driving research that ensures the safe, effective, and equitable access to medicines across Australia and internationally.
Key Takeaways
Gender Disparities in Drug Access: ZOLADEX (goserelin) is a critical hormone therapy used across prostate cancer, premenopausal breast cancer, and fertility preservation. When AstraZeneca removed the drug from the Australian market and the Pharmaceutical Benefits Scheme (PBS), it created a stark equity issue.
Representation Gaps in Clinical Research: Younger women of childbearing age and pregnant women are routinely excluded from major clinical trials due to fertility and safety uncertainties. Because PBAC listing decisions rely heavily on trial data, these exclusions lead to extrapolations that may fail to support optimal real-world access and outcomes for female populations.
Shifting Toward Inclusive Trial Frameworks: While safety concerns historically justified excluding pregnant and childbearing-aged women from research, national frameworks like the National Statement on Ethical Conduct in Human Research are actively working toward safe, inclusive methodologies to fill these critical data gaps.
Addressing Systemic PBS Vulnerabilities: Australia’s PBS operates reactively, depending on pharmaceutical sponsors to apply for listings. To protect patients from unexpected supply disruptions, government bodies must proactively anticipate shortfalls, scout alternative therapies, and secure safeguards before withdrawals occur.
Data-Driven Policy via Medicines Intelligence: Leveraging real-world data is essential for rapid government action. Collaborations between policymakers and research hubs—such as the Centre for Research Excellence in Medicines Intelligence—enable monthly evidence updates to the PBAC, helping quantify impacted populations and guide timely funding decisions.
Resources & Links Mentioned in This Episode
Connect With Us
Have questions or feedback? We’d love to hear from you!
Email: meaningofhealth@outlook.com
Instagram: @healthmeanswhat
Facebook: @MeaningofHealth
Website: meaningofhealth.com.au
